Akums Drugs and Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Akums Drugs and Pharmaceuticals's earnings have been declining at an average annual rate of -20%, while the Pharmaceuticals industry saw earnings growing at 16.8% annually. Revenues have been growing at an average rate of 11.5% per year.
Key information
-20.0%
Earnings growth rate
-20.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.5% |
| Return on equity | 0.1% |
| Net Margin | -0.1% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Akums Drugs and Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 41,817 | -40 | 6,918 | 0 |
| 31 Dec 23 | 40,846 | -671 | 6,737 | 0 |
| 30 Sep 23 | 39,875 | -1,302 | 6,555 | 0 |
| 30 Jun 23 | 38,223 | -177 | 6,423 | 0 |
| 31 Mar 23 | 36,572 | 949 | 6,291 | 0 |
| 31 Mar 22 | 36,752 | -2,525 | 5,399 | 0 |
| 31 Mar 21 | 27,262 | 1,227 | 4,541 | 0 |
Quality Earnings: 544222 is currently unprofitable.
Growing Profit Margin: 544222 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if 544222's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare 544222's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 544222 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (19.1%).
Return on Equity
High ROE: 544222 has a negative Return on Equity (0.11%), as it is currently unprofitable.